{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:14:59Z","timestamp":1790828099330,"version":"4.1.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autologous stem cell transplantation (ASCT) is a potentially curative treatment for several hematologic malignancies. However, the short-term cardiotoxic effects of conditioning regimens remain underexplored. This study evaluates echocardiographic changes occurring within the first 100 days after ASCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective single-center study of 205 lymphoma and Multiple Myeloma patients who underwent ASCT at the American University of Beirut Medical Center (AUBMC) between 2013 and 2022. Echocardiographic parameters before ASCT were compared to those obtained 100 days post-transplant. Conditioning regimens for the lymphoma patients included BEAM (carmustine, etoposide, cytarabine, and melphalan), however for the Multiple Myeloma patients, high-dose melphalan (200\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and other chemotherapy-based regimens. Primary outcomes were changes in left ventricular ejection fraction (LVEF) and the incident of new valvular disease. Statistical analyses included paired t-tests, McNemar's test, and chi-square tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 205 patients, 97 (47.3%) had partial remission at transplantation, and 176 (85.9%) had no prior left ventricular (LV) dysfunction. A total of 108 (52.7%) received myeloablative BEAM conditioning. Pre-ASCT, 193 (94.1%) patients had LVEF &amp;gt;50%, compared with 187 (91.2%) at 100 days post-ASCT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.286). The mean LVEF showed a modest but statistically significant decline (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016). The prevalence of valvular abnormalities increased from 86 (42%) to 104 (50.7%) post-ASCT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.073). Pre-existing LV dysfunction was significantly associated with both post-transplant LV dysfunction and valvular disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05, respectively). Male gender was associated with a higher incidence of valvular disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.024). Conditioning intensity, malignancy type, and prior valvular disease were not significantly correlated with cardiac outcomes. Interestingly, 12 patients with baseline LVEF &amp;lt;50% experienced no cardiac events or ICU admissions post-ASCT; 9 of these demonstrated improved LVEF at follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ASCT is associated with mild but statistically significant early declines in LVEF and increased valvular abnormalities within 100 days post-transplant. Early post-ASCT echocardiographic surveillance may enable the detection of subclinical cardiotoxicity. Prospective longitudinal studies are warranted to define the long-term cardiac impact of ASCT and its conditioning regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1809002","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:54:00Z","timestamp":1779944040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jean","family":"El Cheikh","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"El Tannir","sequence":"additional","affiliation":[{"name":"Research Fellow in the Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Awada","sequence":"additional","affiliation":[{"name":"Faculty of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Research Fellow in the Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Moukalled","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Abou Dalle","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Fakhreddine","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Gharzuddin","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Skouri","sequence":"additional","affiliation":[{"name":"Cardiology Program, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.bbmt.2020.03.005","article-title":"Hematopoietic stem cell transplant recipients surviving at least 2 years from transplant have survival rates approaching population levels in the modern era of transplantation","volume":"26","author":"Kliman","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1182\/blood-2019-125232","article-title":"One and half million hematopoietic stem cell transplants (HSCT). dissemination, trends and potential to improve activity by telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)","volume":"134","author":"Niederwieser","year":"2019","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1182\/bloodadvances.2020004167","article-title":"Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma","volume":"5","author":"Dahi","year":"2021","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3747\/co.26.5033","article-title":"A general practitioner\u2019s guide to hematopoietic stem-cell transplantation","volume":"26","author":"Bazinet","year":"2019","journal-title":"Curr Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/23971983221145639","article-title":"Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis","volume":"8","author":"Penglase","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"Vasbinder","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERP-21-0001","article-title":"British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and\/or trastuzumab: guidelines and recommendations","volume":"8","author":"Dobson","year":"2021","journal-title":"Echo Res Pract"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.2459\/JCM.0000000000000374","article-title":"Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: role of echocardiography","volume":"17","author":"Zito","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1182\/blood-2019-127680","article-title":"Role of echocardiography and cardiac biomarkers in early detection of hematopoietic stem cell transplantation associated cardiotoxicity","volume":"134","author":"Oliver","year":"2019","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.bmt.1702466","article-title":"Cardiac systolic function before and after hematopoietic stem cell transplantation","volume":"26","author":"Lehmann","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1016\/j.bbmt.2015.11.775","article-title":"Cardiac risk factors and echocardiographic variables as predictors of mortality in bone marrow transplant patients","volume":"22","author":"Saini","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","first-page":"475","article-title":"Cardiovascular disease after hematopoietic stem cell transplantation in adults: jACC: cardiooncology state-of-the-art review","volume":"6","author":"Gent","year":"2024","journal-title":"Cardio Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18621\/eurj.889233","article-title":"Evaluation of lymphoma patients after hematopoetic stem cell transplantation in terms of early period cardiotoxicity development","volume":"9","author":"\u00c7elik\u00e7i","year":"2023","journal-title":"Eur Res J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1046\/j.1365-2141.2002.03884.x","article-title":"Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia","volume":"119","author":"Hessling","year":"2002","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3346\/jkms.2007.22.2.227","article-title":"Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning","volume":"22","author":"Kim","year":"2007","journal-title":"J Korean Med Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.140766","article-title":"The short-term cardiotoxicity after allogeneic hematopoietic stem cell transplantation: a retrospective single center experience","volume":"7","author":"El Cheikh","year":"2025","journal-title":"Clin Hematol Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","article-title":"Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis","volume":"40","author":"Oyama","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B20","first-page":"1509","article-title":"Successful allogeneic hematopoietic stem cells transplantation with treosulfan-based conditioning despite advanced heart insufficiency","volume":"3","author":"Markiewicz","year":"2018","journal-title":"Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.46765\/2675-374X.2023v4n2p192","article-title":"Cardiotoxicity after autologous hematopoietic stem cell transplantation (AHSCT): longitudinal and observational study","volume":"4","author":"Elias Hallack Neto","year":"2023","journal-title":"J Bone Marrow Transplant Cell Ther"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1809002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:54:10Z","timestamp":1779944050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1809002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2026.1809002"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1809002","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1809002"}}